Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients

Inclusion Criteria: A) Patients presenting with the following history: 1. Histologically-proven colorectal adenocarcinoma 2. Presenting at the time of resection of the primary with one of the following 4 criteria (criteria indicating a high risk of developing PC) : * Minimal PC, resected at the same time as the primary * Ovarian metastases * Rupture of the primary tumour inside the peritoneal cavity, * Iatrogenic rupture of the primary tumour during surgery B) Who have received standard systemic adjuvant chemotherapy (6 months of systemic chemotherapy) : * Chemotherapy with the Folfox 4 regimen (the current standard treatment ; it can be modified in the future in the two groups, if the standard is modified…). * Given on an intent-to-treat basis (it can be stopped prematurely for miscellaneous reasons…); C) Patients who do not present any sign of tumour recurrence at the end of these 6 months of chemotherapy. D) Patients with the following general characteristics: 1. Age between 18 and 70 years, 2. Performance Status WHO \< 2, life expectancy \> 12 weeks, 3. Haematological parameters : Polynuclear neutrophils ³ 1.5x109/L, platelets ³ 100x109/L, 4. Liver function : Total Bilirubin £ 1.5 x ULN, AST (SGOT) et ALT (SGPT) £ 3 x ULN, alkaline phosphatases £ 3 x ULN, 5. Renal function : Plasma creatinine £ 1,25 x ULN, 6. Operable patients, 7. Grade £ 2 peripheral neuropathy (CTC AE v3.0 annex 7) 8. Patients entitled to French National Health Insurance coverage. E)Patients will be informed and a signed consent form will be obtained before initiating any procedure specific to the trial. Exclusion Criteria: 1. Cancers of non colorectal origin, particularly, appendiceal cancers are excluded 2. Patients presenting with a detectable recurrent tumour 3. Grade ≥ 3 Peripheral neuropathy 4. History of cancer (excepted cutaneous basocellullar cancer or in situ carcinoma of the uterine cervix) with a recurrence during the 5 previous years 5. Patients already included in another trial concerning first-line treatment 6) Pregnant women or likely to be pregnant 7\) Persons under guardianship 8) Follow-up impossible for geographic, social or psychological reasons